Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) EBIT (2016 - 2025)

Anaptysbio filings provide 10 years of EBIT readings, the most recent being $66.9 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 10.54% year-over-year to $66.9 million, compared with a TTM value of $47.9 million through Dec 2025, up 257.05%, and an annual FY2025 reading of $47.9 million, up 257.05% over the prior year.
  • EBIT hit $66.9 million in Q4 2025 for Anaptysbio, up from $34.7 million in the prior quarter.
  • The five-year high for EBIT was $74.8 million in Q4 2024, with the low at -$44.4 million in Q1 2023.
  • Median EBIT over the past 5 years was -$27.7 million (2022), compared with a mean of -$15.9 million.
  • The sharpest move saw EBIT crashed 5115.57% in 2022, then soared 277.48% in 2024.
  • Year by year, EBIT stood at -$31.2 million in 2021, then grew by 16.64% to -$26.0 million in 2022, then plummeted by 62.23% to -$42.1 million in 2023, then surged by 277.48% to $74.8 million in 2024, then decreased by 10.54% to $66.9 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $66.9 million, $34.7 million, and -$26.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.